Design, synthesis and evaluation of PPAR gamma binding activity of 2-thioxo-4-thiazolidinone derivatives

Chinese Chemical Letters

Volumn 26, Issue 1, 2015, Pages 63-68

  Zhou, Li ^a   Zhong, Ye ^a   Xue, Meng Zhu ^a   Kuang, Dong ^a   Cao, Xian Wen ^a   Zhao, Zhen Jiang ^a   Li, Hong Lin ^a   Xu, Yu Fang ^a   Wang, Rui ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

2 Thioxo 4 thiazolidinone; Binding activities; Molecular docking; Peroxisome proliferator activated receptor; SAR;

Indexed keywords

EID: 84921025121     PISSN: 10018417     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cclet.2014.10.008     Document Type: Article

References (41)

1. M. Ahmadian, J.M. Suh, and N. Hah PPAR [gamma] signaling and metabolism: the good, the bad and the future Nat. Med. 99 2013 557 566
2. R.M. Evans, G.D. Barish, and Y.X. Wang PPARs and the complex journey to obesity Nat. Med. 10 2004 355 361
3. B.M. Forman, P. Tontonoz, and J. Chen 15-Deoxy-δ 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARgamma Cell 83 1995 803 812
4. P. Tontonoz, and B.M. Spiegelman Fat and beyond: the diverse biology of PPARgamma Annu. Rev. Biochem. 77 2008 289 312
5. T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke The PPARs: from orphan receptors to drug discovery J. Med. Chem. 43 2000 527 550
6. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688
7. I. Issemann, and S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
8. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
9. K. Schoonjans, B. Staels, and J. Auwerx Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression J. Lipid Res. 37 1996 907 925
10. S.M. Rangwala, and M.A. Lazar Peroxisome proliferator-activated receptor gamma in diabetes and metabolism Trends Pharmacol. Sci. 25 2004 331 336
11. G. Chinetti, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation Inflamm. Res. 49 2000 497 505
12. P. Delerive, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptors in inflammation control J. Endocrinol. 169 2001 453 459
13. D.J. Mangelsdorf, C. Thummel, and M. Beato The nuclear receptor superfamily: the second decade Cell 83 1995 835 839
14. R.K. Chaturvedi, and M.F. Beal PPAR: a therapeutic target in Parkinson's disease J. Neurochem. 106 2008 506 518
15. S.H. Caldwell, E.E. Hespenheide, and J.A. Redick A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis Am. J. Gastroenterol. 96 2001 519 525
16. M. Diamant, and R.J. Heine Thiazolidinediones in type 2 diabetes mellitus Drugs 63 2003 1373 1406
17. J.M. Lehmann, L.B. Moore, and T.A. Smith-Oliver An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma) J. Biol. Chem. 270 1995 12953 12956
18. H. Yki-Järvinen Thiazolidinediones N. Engl. J. Med. 351 2004 1106 1118
19. B. Staels, and J.C. Fruchart Therapeutic roles of peroxisome proliferator-activated receptor agonists Diabetes 54 2005 2460 2470
20. T.M. Willson, J.E. Cobb, and D.J. Cowan The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones J. Med. Chem. 39 1996 665 668
21. B.A. Neuschwander-Tetri, W.L. Isley, and J.C. Oki Troglitazone-induced hepatic failure leading to liver transplantation: a case report Ann. Intern. Med. 129 1998 38 41
22. J. Cohen Risks of troglitazone apparent before approval in USA Diabetologia 49 2006 1454 1455
23. R.A. Daynes, and D.C. Jones Emerging roles of PPARs in inflammation and immunity Nat. Rev. Immunol. 2 2002 748 759
24. F. Calon, Y.H. Zhao, C. Julien, and J.W. Winkler Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARgamma mediated mechanisms in Alzheimer's disease models Plos One 6 2011 1 15
25. H.L.X. Zhang, M. Wei, and C. Qin Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-kappaB signaling pathway Neuroscience 176 2011 381 395
26. A.L.F. Gabriel Pascual, S. Ogawa, and A. Gamliel A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma Nature 437 2005 759 763
27. M.T. Heneka, T. Klockgether, and D.L. Feinstein Peroxisome proliferator-activated receptor-g ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo J. Neurosci. 20 2000 6862 6867
28. G. Landreth, Q. Jiang, S. Mandrekar, and M. Heneka PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease Neurotherapeutics 5 2008 481 489
29. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 2007 2457 2471
30. B.M. Psaty, and C.D. Furberg The record on rosiglitazone and the risk of myocardial infarction N. Engl. J. Med. 357 2007 67 69
31. L. Azoulay, H. Yin, and K.B. Filion The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study Br. Med. J. 344 2012 e3645
32. J.D. Lewis, A. Ferrara, and T. Peng Risk of bladder cancer among diabetic patients treated with pioglitazone interim report of a longitudinal cohort study Diabetes Care 34 2011 916 922
33. A.M. Lincoff, K. Wolski, S.J. Nicholls, and S.E. Nissen Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus J. Am. Med. Assoc. 298 2007 1180 1188
34. C. Day Thiazolidinediones: a new class of antidiabetic drugs Diabetic Med. 16 1999 179 192
35. F.J. Schopfer, M.P. Cole, and A.L. Groeger Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids selective ligand activity and anti-diabetic signaling actions J. Biol. Chem. 285 2010 12321 12333
36. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
37. X. Liu, H. Jiang, and H. Li SHAFTS: a hybrid approach for 3D molecular similarity calculation. 1. Method and assessment of virtual screening J. Chem. Inf. Model. 51 2011 2372 2385
38. X. Liu, F. Bai, and S. Ouyang Cyndi: a multi-objective evolution algorithm based method for bioactive molecular conformational generation BMC Bioinformatics 10 2009 101
39. R.T. Nolte, G.B. Wisely, and S. Westin Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma Nature 395 1998 137 143
40. G. Bruno, L. Costantino, and C. Curinga Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones Bioorg. Med. Chem. 10 2002 1077 1084
41. A.G. Chittiboyina, M.S. Venkatraman, and C.S. Mizuno Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists J. Med. Chem. 49 2006 4072 4084